CHARGEPOINT INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies ChargePoint Investors of a Class Action Lawsuit and Upcoming Deadline
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
December 04, 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc
DOLLAR GENERAL INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Dollar General investors of a Class Action Lawsuit and Upcoming Deadline
December 01, 2023 22:52 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased the common stock of Dollar General Corp
CHARGEPOINT INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies ChargePoint Investors of a Class Action Lawsuit and Upcoming Deadline
November 30, 2023 18:42 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired ChargePoint Holdings, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
November 30, 2023 16:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
November 30, 2023 16:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
November 29, 2023 14:50 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX).
Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN)
November 28, 2023 13:44 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased Acelyrin, Inc. (Nasdaq: SLRN) common stock.
SUNPOWER INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies SunPower Investors of a Class Action Lawsuit and Upcoming Deadline
November 27, 2023 10:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired SunPower Corporation.
THE BEAUTY HEALTH COMPANY INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies Beauty Health Investors of a Class Action Lawsuit and Upcoming Deadline
November 22, 2023 15:29 ET
|
Kaplan Fox & Kilsheimer LLP
Beauty Health Investor Notice.